Browsing by Subject "Discovery"

Now showing 1 - 6 of 6
  • Thumbnail Image
    Item
    472 Indiana CTSI Think Tank Program
    (Cambridge University Press, 2022) Garcia, Kara; Portonovo, Padma; Garci, Kara; Medicine, School of Medicine
    OBJECTIVES/GOALS: The Think Tanks’ aim to assist faculty innovators along the path from discovery to commercialization; serving as a one-stop-shop where investigators can access advice, pilot funds, and direction toward other available resources within the Indiana CTSI. METHODS/STUDY POPULATION: Faculty receive guidance from a pool of advisors in the drug and device industry, as well as their respective university commercialization offices; who serve as an essential resource for a wide range of scientific, technical, clinical, business, and regulatory questions. Investigators submit a simple intake form to connect with a project facilitator for detailed guidance prior to formal meetings. Projects are guided from start to finish with robust tracking and milestone-based funding to help generate data for Investigational New Drug (IND) or Investigational Device Exemption (IDE) applications. Project tracking is conducted using REDCap, which is used for all investigator submissions, with internal processes also tracked in REDCap. RESULTS/ANTICIPATED RESULTS: From Feb-Aug 2021; the Think Tanks provided feedback to 15 drug projects and 6 medical device projects. This included 12 from Indiana University; 4 from Purdue University; and 5 from the University of Notre Dame. Interestingly; drug innovations were submitted primarily by tenure track faculty (100%) with a history of NIH/NSF funding (50%); while device innovations were submitted primarily by clinical faculty without a history of NIH/NSF funding (66%). Based on first-round feedback, a total of approximately $3;400 in pilot funds were provided. Efforts are underway to obtain survey-based feedback from all applicants to date; which will be used to inform future program modifications. DISCUSSION/SIGNIFICANCE: The budding “Think Tank” program provides faculty with a broad perspective of the entire drug and medical device development process, helping investigators understand the critical interplay development stages. Future work seeks to enhance faculty engagement in, and understanding of the commercialization process across Indiana CTSI institutions.
  • Thumbnail Image
    Item
  • Thumbnail Image
    Item
    Chapter 13: Intellectual Property Issues Raised by Email
    (2014) Smith, Michael B.; Hook, Sara Anne; Dossa, Aly
  • Thumbnail Image
    Item
    Discovery Under the New Federal Rules of Civil Procedure
    (2016) Hook, Sara Anne
    The amendments to the Federal Rules of Civil Procedure (FRCP) have brought significant changes to e-discovery and litigation strategy. Are you taking full advantage of these changes? Learn how to apply the proportionality standard, new guidelines on spoliation and more to the next case. Presenters will explain how to adapt current e-discovery process to make the new FRCP changes work in daily law practice. Recognize how the amended rules speed up early stage litigation. Learn to interpret the new scope of discovery under Rule 26(b). Prepare for the practical impact of proportionality on your case. Master new preservation standards and upgrade your use of litigation holds. Get tips for drafting specific discovery requests and shifting discovery costs. Avoid ethical pitfalls when collecting and reviewing social media evidence.
  • Thumbnail Image
    Item
    Intellectual Property Law in Cyberspace, 2nd ed. 2015 Cummulative Supplement
    (2015) Hook, Sara Anne; Smith, Michael B.; Dossa, Aly
  • Thumbnail Image
    Item
    Novel Immune-Based treatments for Diffuse Large B-Cell Lymphoma: The Post-CAR T Cell Era
    (Frontiers Media, 2022-06-01) Atallah-Yunes, Suheil Albert; Robertson, Michael J.; Davé, Utpal P.; Ghione, Paola; Perna, Fabiana; Medicine, School of Medicine
    Prognosis for patients with refractory/relapsed (R/R) diffuse large B-cell lymphoma (DLBCL) is poor. Immune-based therapeutic treatments such as CD19 Chimeric Antigen Receptor (CAR) T cell therapies have dramatically changed the treatment landscape for R/R DLBCL leading to durable remissions in ~ 50% of patients. However, there remains an unmet need for developing novel therapies to improve clinical outcomes of patients not responding or relapsing after CAR T cell therapies. Lack of suitable immunotherapeutic targets and disease heterogeneity represent the foremost challenges in this emerging field. In this review, we discuss the recently approved and emerging novel immunotherapies for patients with R/R DLBCL in the post-CAR T era and the cell surface targets currently used.